Results 311 to 320 of about 742,288 (358)
Some of the next articles are maybe not open access.
Cardiovascular Protection with Anti-hyperglycemic Agents
American Journal of Cardiovascular Drugs, 2019Diabetes mellitus is a major risk factor for cardiovascular (CV) disease. Conversely, CV disease is responsible for a majority of the deaths in patients with diabetes. Many drug trials have concentrated on blood glucose (hemoglobin A1c) reduction. This strategy, while reducing microvascular outcomes like nephropathy and neuropathy, has little or no ...
Prakash, Deedwania, Tushar, Acharya
openaire +2 more sources
Oral antiplatelet agents in cardiovascular disease
Vasa, 2019Abstract. Antiplatelet agents significantly reduce mortality and morbidity in ischemic heart disease, cerebrovascular disease and peripheral artery disease (PAD), and are therefore part of guideline-driven daily medical treatment in these patients. Due to its beneficial effects in the secondary prevention of atherothrombotic events, aspirin remains ...
Joseph, Pultar +3 more
openaire +2 more sources
Cardiovascular effects of contrast agents
The American Journal of Cardiology, 1989Iodinated radiologic contrast agents should, ideally, passively provide radiographic contrast in blood vessels and soft tissues but have no effects on physiology, hematology or biochemistry. In practice, no such agent exists although the nonionics most closely approach the ideal.
openaire +2 more sources
Antihyperglycemic agents and cardiovascular outcomes
Current Opinion in Cardiology, 2017To summarize cardiovascular outcome trials (CVOTs) with antihyperglycemic agents conducted since 2008 US Food and Drug Administration guidance.A series of large CVOTs since 2008 have included patients with type 2 diabetes (T2D), who are otherwise treated according to standard of care.
Harpreet S, Bajaj +2 more
openaire +2 more sources
Aryl-2-piperidylcarbinols: Potential Cardiovascular Agents
Journal of Pharmaceutical Sciences, 1971Abstract The syntheses of some substituted aryl-2-piperidylcarbinols are described. Weak α- and/or β-agonist and/or antagonist activity was observed in preliminary experimental studies in animals.
J, Sam, D N, Vacik, M N, Aboul-Enein
openaire +2 more sources
Cardiovascular toxicity of molecularly targeted agents
European Journal of Cancer, 2009Over the last decade, molecularly targeted drugs have become established in oncology therapeutics and clinical research. While initially marketed as “cancer specific” agents with superior toxicity profiles to conventional anti-proliferative and DNA-damaging chemotherapy, it has become increasingly apparent that these drugs have numerous serious “on ...
Elizabeth L, Strevel, Lillian L, Siu
openaire +2 more sources
Urokinase-a Very Popular Cardiovascular Agent
Recent Patents on Cardiovascular Drug Discovery, 2008Urokinase (UK) [EC 3.4.99.26] is a serine protease that activates plasminogen to plasmin, which in turn degrades fibrin clots. Hence, UK finds its value as an important anti-thromboembolic drug. Plasmin has diverse physiological roles apart from its fibrinolytic role in the regulation of blood clotting.
Adinarayana, Kunamneni +4 more
openaire +2 more sources
Novel Antiplatelet Agents in Cardiovascular Medicine
Current Treatment Options in Cardiovascular Medicine, 2015Dual antiplatelet therapy with aspirin and a P2Y12 receptor blocker, particularly clopidogrel, has been the standard of therapy for secondary prevention in patients with acute coronary syndromes and patients treated with percutaneous coronary intervention.
Rahil, Rafeedheen +4 more
openaire +2 more sources